Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 403-409, 2004. First published December 18, 2003; 10.1373/clinchem.2003.027169
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Suppplement
Right arrow All Versions of this Article:
clinchem.2003.027169v1
50/2/403    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Valianpour, F.
Right arrow Articles by Kulik, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valianpour, F.
Right arrow Articles by Kulik, W.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Pediatric Clinical Chemistry
Right arrow Endocrinology and Metabolism
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2004;50:403-409.)
© 2004 American Association for Clinical Chemistry, Inc.

Automation and Analytical Techniques

Quantification of Free Sialic Acid in Urine by HPLC–Electrospray Tandem Mass Spectrometry: A Tool for the Diagnosis of Sialic Acid Storage Disease

Fredoen Valianpour1, Nicolaas G.G.M. Abeling1, Marinus Duran1, Jan G.M. Huijmans2 and Willem Kulik1,a

1 Academic Medical Center, University of Amsterdam, Laboratory Genetic Metabolic Diseases, Emma Children’s Hospital and Department of Clinical Chemistry, Amsterdam, The Netherlands.
2 Erasmus Medical Center, Department of Clinical Genetics, Rotterdam, The Netherlands.

aAddress correspondence to this author at: Laboratory Genetic Metabolic Diseases, F0-224, PO Box 22700, 1100 DE Amsterdam, The Netherlands. Fax 31-20-6962596; e-mail w.kulik{at}amc.uva.nl.

Background: Sialic acid storage diseases (SSDs) are severe autosomal recessive neurodegenerative disorders caused by a transport defect across the lysosomal membrane, which leads to accumulation of sialic acid in tissues, fibroblasts, and urine. Defective free sialic acid transport can be established by quantification of free sialic acid in urine.

Methods: Urine sample size was adjusted to the equivalent of 100 nmol of creatinine. After addition of 2-keto-3-deoxy-D-glycero-D-galactonononic acid as internal standard, samples were diluted with water to an end volume of 250 µL. We used 10 µL for HPLC–tandem mass spectrometric analysis in the negative electrospray ionization mode, monitoring transitions m/z 308.3->m/z 86.9 (sialic acid) and m/z 267.2->m/z 86.9 (internal standard). The overall method was validated and studied for ion suppression, interfering compounds, and pH effects. Samples from controls (n = 72) and SSD patients (n = 3) were analyzed.

Results: The limit of detection was 3 µmol/L. Intraassay imprecision (CV; n = 10) was 6%, 3%, and 2% at 30, 130, and 1000 mmol/mol creatinine, respectively; corresponding interassay CV (n = 10) were 5%, 5%, and 2%. Recovery was 109% (100–1000 mmol/mol creatinine). The mean (SD) [range] excretion rates (mmol/mol creatinine) were 31.3 (16.6) [0.7–56.9] at 0–1 year (n = 20), 21.2 (9.8) [6.3–38.3] at 1–3 years (n = 15), 14.4 (8.2) [1.7–32.9] at 3–10 years (n = 25), and 4.6 (2.6) [0–9.8] above age 10 years (n = 12). SSD patients 1.2, 3.9, and 12 years of age had concentrations of 111.5, 54.2, and 36.1 mmol/mol creatinine, respectively.

Conclusions: The HPLC-tandem MS method for free sialic acid in urine is more rapid, accurate, sensitive, selective, and robust than earlier methods and may serve as a candidate reference method for free sialic acid in diagnosis of SSD.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
E. Roura, C. Andres-Lacueva, R. Estruch, and R. M. Lamuela-Raventos
Total Polyphenol Intake Estimated by a Modified Folin-Ciocalteu Assay of Urine
Clin. Chem., April 1, 2006; 52(4): 749 - 752.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
R Froissart, D Cheillan, R Bouvier, S Tourret, V Bonnet, M Piraud, and I Maire
Clinical, morphological, and molecular aspects of sialic acid storage disease manifesting in utero
J. Med. Genet., November 1, 2005; 42(11): 829 - 836.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Ma, F. M. Vaz, Z. Gu, R. J. A. Wanders, and M. L. Greenberg
The Human TAZ Gene Complements Mitochondrial Dysfunction in the Yeast taz1{Delta} Mutant: IMPLICATIONS FOR BARTH SYNDROME
J. Biol. Chem., October 22, 2004; 279(43): 44394 - 44399.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.